Edition:
United Kingdom

Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

21 Jun 2017

Drugmaker Mylan gets boost from unlikely source: coal

NEW YORK Mylan N.V. is best known for producing EpiPen emergency allergy treatments and generic drugs.

31 May 2017

Mylan may have overcharged U.S. for EpiPen by $1.27 bln -HHS

NEW YORK The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.

31 May 2017

Mylan may have overcharged U.S. for EpiPen by $1.27 billion - HHS

NEW YORK The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion (985.72 million pounds) between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.

10 May 2017

Mylan disagrees with FDA over generic Advair delay

Generic drug maker Mylan NV on Wednesday said it disagrees with the reasoning behind the U.S. Food and Drug Administration's decision not to approve its generic for GlaxoSmithKline Plc's blockbuster Advair in March. | Video

09 May 2017

Allergan posts loss as it writes down Teva holdings

Botox-maker Allergan Plc posted a first-quarter loss on Tuesday as it took a nearly $2 billion write-down on the value of its stake in Teva Pharmaceutical Industries , which has lost more than 40 percent of its value since last year.

02 May 2017

Prescription for growth at Pfizer? Analysts say, deals

Pfizer Inc posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects.

02 May 2017

Prescription for growth at Pfizer? Analysts say deals

Pfizer Inc posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects.

28 Apr 2017

Kentucky's pension deal offers lessons on risks, cost cuts

NEW YORK When Kentucky's public pension put U.S. buyout firm KKR & Co LP in charge of its hedge fund investments in May 2015, its board expected the deal to save money and boost its returns.

27 Apr 2017

Bristol-Myers' cancer drug Opdivo fuels Wall Street beat

NEW YORK Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs.

27 Apr 2017

Bristol-Myers beats Wall St estimates, helped by Cancer drug Opdivo

NEW YORK, April 27 Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth from cancer drugs Opdivo and Yervoy and blood thinner Eliquis.

More From Around the Web

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,434.36 -12.44 -0.17%
DAX 12,671.02 -99.81 -0.78%
CAC 40 5,258.58 -37.17 -0.70%
TR Europe 174.42 + 0.09 +0.05%
GBP/USD 1.2617 -0.90%
GBP/EUR 1.1340 -0.72%
EUR/USD 1.1124 -0.22%
Gold 1,240.70 -3.50 -0.28%
Oil 44.15 +0.77 +1.78%
Corn 360.75 +1.75 +0.49%